Jay M. Moyes Sells 22,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Jay M. Moyes sold 22,000 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.40, for a total value of $74,800.00. Following the transaction, the director now directly owns 53,322 shares in the company, valued at approximately $181,294.80. This represents a 29.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Puma Biotechnology Trading Down 0.6%

Puma Biotechnology stock traded down $0.02 during trading hours on Tuesday, reaching $3.43. The company had a trading volume of 210,811 shares, compared to its average volume of 443,805. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.53 and a quick ratio of 1.43. The company has a 50-day moving average price of $3.20 and a 200 day moving average price of $3.12. The firm has a market cap of $170.23 million, a price-to-earnings ratio of 4.45 and a beta of 1.29. Puma Biotechnology, Inc. has a 12-month low of $2.23 and a 12-month high of $4.13.

Hedge Funds Weigh In On Puma Biotechnology

A number of large investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its stake in Puma Biotechnology by 3.8% in the 1st quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company's stock worth $254,000 after purchasing an additional 3,117 shares during the period. LPL Financial LLC increased its stake in shares of Puma Biotechnology by 23.6% during the fourth quarter. LPL Financial LLC now owns 26,567 shares of the biopharmaceutical company's stock valued at $81,000 after buying an additional 5,080 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Puma Biotechnology by 42.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,083 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 5,726 shares during the period. Prudential Financial Inc. increased its stake in shares of Puma Biotechnology by 5.8% during the fourth quarter. Prudential Financial Inc. now owns 106,285 shares of the biopharmaceutical company's stock valued at $324,000 after buying an additional 5,800 shares during the period. Finally, Wells Fargo & Company MN increased its stake in shares of Puma Biotechnology by 36.5% during the fourth quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company's stock valued at $70,000 after buying an additional 6,126 shares during the period. 61.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PBYI has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Friday, February 28th. Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.